We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter, retrospective analysis included 406 men with prostate cancer who underwent 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into a very low (quintile 1, ≤25 cm3), low (quintile 2, 25–189 cm3), moderate (quintile 3, 189–532 cm3), high (quintile 4, 532–1,355 cm3), or very high (quintile 5, ≥1,355 cm3) total PSMA-positive tumor volume (PSMA-VOL). PSMA-VOL was obtained by semiautomatic segmentation of total tumor lesions using qPSMA software. Fifty prostate cancer patients with no PSMA-p...
The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is...
Purpose: Recently, a significant association was shown between novel growth patterns on histopatholo...
Purpose: To determine the impact on clinical management of patients with high-risk (HR) prostate can...
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane a...
Purpose: Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and r...
Recently, a 18F-labeled derivative of the widely used 68Ga-PSMA-11 was developed for PET imaging of ...
PURPOSE The aim of our study is to assess the pharmacokinetics and biodistribution of Ga-PSMA-11 ...
AbstractContext68Gallium prostate-specific membrane antigen (PSMA) ligand 68Ga-HBED-CC-PSMA (68Ga-PS...
PURPOSE PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on trea...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
PURPOSE: Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases pr...
Background: To determine the potential role of Ga-68-PSMA positron emission tomography/computed tomo...
Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in patients with pro...
BACKGROUND: The purpose of this study was to evaluate the imaging properties of hepatic metastase...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is...
Purpose: Recently, a significant association was shown between novel growth patterns on histopatholo...
Purpose: To determine the impact on clinical management of patients with high-risk (HR) prostate can...
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane a...
Purpose: Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and r...
Recently, a 18F-labeled derivative of the widely used 68Ga-PSMA-11 was developed for PET imaging of ...
PURPOSE The aim of our study is to assess the pharmacokinetics and biodistribution of Ga-PSMA-11 ...
AbstractContext68Gallium prostate-specific membrane antigen (PSMA) ligand 68Ga-HBED-CC-PSMA (68Ga-PS...
PURPOSE PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on trea...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
PURPOSE: Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases pr...
Background: To determine the potential role of Ga-68-PSMA positron emission tomography/computed tomo...
Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in patients with pro...
BACKGROUND: The purpose of this study was to evaluate the imaging properties of hepatic metastase...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is...
Purpose: Recently, a significant association was shown between novel growth patterns on histopatholo...
Purpose: To determine the impact on clinical management of patients with high-risk (HR) prostate can...